Arvinas Stock Forecast
NASDAQ: ARVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 1:37 PM ET
ARVN analyst consensus
Consensus (16 analysts)
buy
Avg. price target
$13.93+80.91%
- Strong buy 2
- Buy 5
- Hold 8
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 16 Wall Street analysts covering Arvinas (2026-10-08), 7 rate the stock a buy or strong buy, 8 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $13.93, with a high estimate of $21.00 and a low estimate of $6.00. The average target implies upside of 80.9% from the current price of $7.70.
The spread between the highest and lowest targets is 250.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ARVN.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 13% |
| Buy | 5 | 31% |
| Hold | 8 | 50% |
| Sell | 1 | 6% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.00 | -22.08% |
| Average target | $13.93 | +80.91% |
| High target | $21.00 | +172.73% |